共 50 条
Overcoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers
被引:2
|作者:
Kadhum, Wesam R.
[1
,2
]
Majeed, Ali A.
[3
]
Saleh, Raed Obaid
[4
]
Ali, Eyhab
[5
]
Alhajlah, Sharif
[6
]
Alwaily, Enas R.
[7
]
Mustafa, Yasser Fakri
[8
]
Ghildiyal, Pallavi
[9
]
Alawadi, Ahmed
[10
,11
,12
]
Alsalamy, Ali
[13
]
机构:
[1] Kut Univ Coll, Dept Pharm, Kut 52001, Wasit, Iraq
[2] Kut Univ Coll, Adv Res Ctr, Kut 52001, Wasit, Iraq
[3] Univ Kufa, Fac Sci, Dept Pathol Anal, Najaf, Iraq
[4] Al Maarif Univ Coll, Dept Med Lab Tech, Al Anbar, Iraq
[5] Al Zahraa Univ Women, Pharm Dept, Karbala, Iraq
[6] Shaqra Univ, Coll Appl Med Sci, Dept Med Labs, Shaqra 11961, Saudi Arabia
[7] Al Ayen Univ, Coll Pharm, Microbiol Res Grp, Thi Qar, Iraq
[8] Univ Mosul, Coll Pharm, Dept Pharmaceut Chem, Mosul, Iraq
[9] Uttaranchal Univ, Uttaranchal Inst Pharmaceut Sci, Dehra Dun, Uttarakhand, India
[10] Islamic Univ, Coll Tech Engn, Najaf, Iraq
[11] Islamic Univ Al Diwaniyah, Coll Tech Engn, Al Diwaniyah, Iraq
[12] Islamic Univ Babylon, Coll Tech Engn, Babylon, Iraq
[13] Imam Jaafar Al Sadiq Univ, Coll Tech Engn, Al Muthanna, Iraq
关键词:
Targeted Therapy;
Metastatic cancer;
Scales;
Nano drug;
Signaling;
SOLID LIPID NANOPARTICLES;
ENHANCED PERMEABILITY;
REXIN-G;
GENETIC-HETEROGENEITY;
INTRINSIC RESISTANCE;
MULTIDRUG-RESISTANCE;
DELIVERY SYSTEMS;
SINGLE-AGENT;
LUNG-CANCER;
IN-VITRO;
D O I:
10.1016/j.prp.2024.155137
中图分类号:
R36 [病理学];
学科分类号:
100104 ;
摘要:
Metastatic cancer, which accounts for the majority of cancer fatalities, is a difficult illness to treat. Currently used cancer treatments include radiation therapy, chemotherapy, surgery, and targeted treatment (immune, gene, and hormonal). The disadvantages of these treatments include a high risk of tumor recurrence and surgical complications that may result in permanent deformities. On the other hand, most chemotherapy drugs are small molecules, which usually have unfavorable side effects, low absorption, poor selectivity, and multi-drug resistance. Anticancer drugs can be delivered precisely to the cancer spot by encapsulating them to reduce side effects. Stimuli-responsive nanocarriers can be used for drug release at cancer sites and provide target-specific delivery. As previously stated, metastasis is the primary cause of cancer-related mortality. We have evaluated the usage of nano-medications in the treatment of some metastatic tumors.
引用
收藏
页数:10
相关论文